Borderline personality disorder personality problems
Conditions
Interventions
1. Dialectical Behavior Therapy (DBT)
2. Schema Therapy (ST)
There are two different intervention conditions, DBT or ST, which participants
are randomly assigned to. Both treatments will consist of
Sponsors
Universiteit van Amsterdam
Eligibility
Age
18 Years to 99 Years
Inclusion criteria
Inclusion criteria: 1. Primary diagnosis of BPD 2. Age 18-65 years 3. Borderline Personality Disorder Severity Index, fifth edition (BPDSI-5) score above 20 4. Dutch literacy 5. The willingness and ability to participate in (group) treatment for a maximum of 24 months and to complete the assessments over a period of three years
Exclusion criteria
Exclusion criteria: 1. Psychotic disorder in the past year (except short reactive psychotic episodes, see BPD criterion 9 of the DSM 5) 2. Severe addiction requiring clinical detoxification (after which entering is possible) 3. Bipolar I disorder with at least one manic episode in the past year 4. IQ
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| The primary outcome measure is change in the severity and frequency of the DSM-5 BPD manifestations (BPDSI-5, total score; Arntz et al., 2003; Giesen-Bloo, Wachters, Schouten, & Arntz, 2010). This outcome measure is frequently used in other studies of ST: Giesen-Bloo et al. (2006), Van Asselt et al. (2008), Nadort et al. (2009), and Wetzelaer et al. (2014). | — |
Secondary
| Measure | Time frame |
|---|---|
| As accumulating evidence suggests that symptoms and level of functioning are only loosely associated, attention will be paid to outcome in terms of both symptom change and functioning, including relational, occupational, and personal (wellbeing) functioning. Therefore, the secondary outcome measures will include: - DSM-5 diagnostic status, assessed by the Structured Clinical Interviews for the Diagnostic and Statistical Manual of Mental Disorders-5 (DSM-5) Clinician Version (SCID-5-CV) and Personality Disorders (SCID-5-PD). - BPDSI-5 (Arntz et al., 2003; Giesen-Bloo et al., 2010) reliable change and recovery (i.e., score below 15). - Dimensional scores for each of the DSM-5 BPD-criteria as assessed with the BPDSI-5 (Arntz et al., 2003; Giesen-Bloo et al., 2006). - Psychopathology, personality characteristics, and behavioral proclivities, assessed by the Minnesota Multiphasic Personality Inventory-2 Restructured Form (MMPI-2-rf; Ben-Porath & Tellegen, 2008). - General functioning, including work/study and societal participation, assessed by the WHO Disability Assessment Schedule (WHODAS 2.0; Üstün, Kostanjsek, Chatterji, & Rehm, 2010). - General psychopathology as measured with the Brief Symptom Inventory (BSI; Derogatis & Melisaratos, 1983). - Quality of life, assessed using the EuroQol EQ-5D-5L (Rabin & Charro, 2001) and the Mental Health Quality of Life seven-dimensional Questionnaire (MHQoL-7D; van Krugten et al., 2019). - Happiness, measured with a single question on general happiness (Veenhoven, 2008). - Sleep, measured using the Insomnia Sleep Index (Bastien, Vallières, & Morin, 2001) and two items measuring nightmare frequency. - Costs, including healthcare, patient and family costs and costs outside the health care sector, will be measured using a retrospective cost interview especially designed for BPD patients (Wetzelaer et al., 2014). - A subgroup of patients (N=30) will receive two additional questionnaires, including the Y | — |
Countries
Netherlands
Outcome results
None listed